| Matheau A Julien, MD | |
|
251 E Huron St, Galter 3-150, Chicago, IL 60611-2908 | |
| (312) 926-6512 | |
| Not Available |
| Full Name | Matheau A Julien |
|---|---|
| Gender | Male |
| Speciality | Cardiac Surgery |
| Experience | 18 Years |
| Location | 251 E Huron St, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619189933 | NPI | - | NPPES |
| 036139510 | Other | IL | ILLINOIS DEPARTMENT OF FINANCIAL AND PROFESSIONAL REGULATION |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern Illinois Medical Services Nfp | 3678677390 | 254 |
| Carle West Physician Group Inc | 8921420308 | 254 |
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
| Entity Name | Rockford Health Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043242886 PECOS PAC ID: 2567374036 Enrollment ID: O20031103000584 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
| Entity Name | Southern Illinois Medical Services Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770656837 PECOS PAC ID: 3678677390 Enrollment ID: O20070404000595 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
| Entity Name | Carle Health Care Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154653947 PECOS PAC ID: 3577515774 Enrollment ID: O20100513000829 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
| Entity Name | Carle West Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467074138 PECOS PAC ID: 8921420308 Enrollment ID: O20200613000147 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matheau A Julien, MD 251 E Huron St, Galter 3-150, Chicago, IL 60611-2908 Ph: (312) 926-6512 | Matheau A Julien, MD 251 E Huron St, Galter 3-150, Chicago, IL 60611-2908 Ph: (312) 926-6512 |
News Archive
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Researchers in the North West are investigating whether tools pioneered in aviation security can be used to help prevent complications after surgery.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal 2010, ended September 30, 2009.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Muscle deterioration in patients with lung diseases might be a direct consequence of high carbon dioxide levels in their blood, an international team of researchers headed by Prof. Yosef Gruenbaum of the Hebrew University of Jerusalem has found.
› Verified 6 days ago
Ankit Bharat, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 676 N Saint Clair St, Suite 650, Chicago, IL 60611 Phone: 312-926-7628 | |
Prof. Cemil Selim Isbir, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 215 W Lake St Apt 1308, Chicago, IL 60606 Phone: 310-623-0850 | |
Dr. Marshall David Goldin, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1725 W Harrison St, Suite 1156, Chicago, IL 60612 Phone: 312-563-2763 | |
Tae H Song, Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Michael C Monge, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 225 E Chicago Ave # 22, Cardiovascular Surgery, Chicago, IL 60611 Phone: 312-227-4240 Fax: 312-227-9643 | |
Miss Keiko Okumura, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1635 West Congress Parkway, Chicago, IL 60612 Phone: 312-943-6370 Fax: 312-943-6052 | |
Andre Young Son, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 675 N Saint Clair St Ste 19-100, Chicago, IL 60611 Phone: 312-664-3278 Fax: 312-695-2461 |